Clinical Trials Logo

Node-positive Breast Cancer clinical trials

View clinical trials related to Node-positive Breast Cancer.

Filter by:

NCT ID: NCT05970107 Not yet recruiting - Clinical trials for Node-positive Breast Cancer

Axillary Node Dissection w or w/o LVB in Node Positive Breast Cancer Patients

Start date: October 1, 2024
Phase: N/A
Study type: Interventional

Lymphedema is a devastating complication of breast cancer surgery that decreases the quality of life of up to 40% of breast cancer survivors. Most lymphedema in breast cancer patients is because lymphatics shared between the axilla and the arm are sacrificed during axillary lymph node dissection (ALND) surgery, which removes an average of 15 lymph nodes in node positive patients. CCF's breast cancer plastic microvascular surgeons and breast surgical oncologists have collaborated to refine a surgical technique known as LVB that may be used either as a preventive measure (prophylactic LVB) or as a therapeutic intervention (therapeutic LVB). Lymphatic reconstruction with LVB may be an improvement to the current standard of care for node positive breast cancer patients undergoing ALND.

NCT ID: NCT05676866 Not yet recruiting - Clinical trials for Node-positive Breast Cancer

Evaluation of Targeted Axillary Lymph Node Dissection in Node Positive Breast Cancer Patients Post Neo Adjuvant Therapy

Start date: December 1, 2023
Phase: Phase 4
Study type: Interventional

evaluation of targeted axillary lymph node dissection in node positive breast cancer patients post neo adjuvant therapy

NCT ID: NCT05462457 Recruiting - Breast Cancer Clinical Trials

TAD in Primary Breast Cancer With Initially ≥ 3 Suspicious Lymph Nodes

SenTa2
Start date: March 7, 2022
Phase:
Study type: Observational

Due to high pathological complete remission (pCR) rates in both breast and lymph nodes (ypT0/Tis, ypN0) following neoadjuvant systemic therapy (NST) in many patients with initially clinically node-positive (cN+) breast cancer, the standard treatment of the axilla has changed from axillary lymph node dissection (ALND), which is associated with high morbidity, to less invasive, surgical approaches. In several studies, targeted axillary dissection (TAD) has presented with false-negative rates (FNRs) less than 5%, however, in patients with high initial lymph node involvement (≥ 3 clinically suspicious lymph nodes) TAD has not been thoroughly investigated. The present prospective registry study aims to evaluate the FNR of TAD in patients with ≥ 3 initially suspicious lymph nodes and clinically node-negative status (ycN0) after NST in comparison to ALND.

NCT ID: NCT05333328 Recruiting - Breast Cancer Clinical Trials

OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk

INTERSTELLAR
Start date: February 6, 2023
Phase: Phase 4
Study type: Interventional

Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®). In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.

NCT ID: NCT04826211 Recruiting - Clinical trials for Breast Cancer Female

Axillary Staging in Node Positive Breast Cancer Patients Receiving PST. SNB vs PET/MRI

Start date: November 4, 2019
Phase: N/A
Study type: Interventional

The management of axillary nodes in breast cancer patients is a highly debated and evolving field. To date, an increasing number of patients with positive lymph nodes receives primary systemic therapy (PST) prior to surgery leading to down-staging axillary nodes in about 40% of women. However, the available diagnostic methods have several limitations in properly evaluating the response after treatment both in the breast and in the nodes and might lead to either under or over-treatment in these patients. Fully integrated scanners capable of simultaneous acquisition of PET and MRI have now been developed, with the potential to combine the specificity obtained by the functional imaging of PET, with the superior sensitivity of MRI, to provide higher diagnostic accuracy. It is expected that PET/MRI could better determine the response after PST to distinguish patients with negative versus patients with positive axillary nodes after medical treatment. As the excision of axillary nodes has mainly a staging purpose, the reliable identification of node negative patients might eventually spare women from unnecessary surgery. An accurate over-time and final imaging work-up might help choose the appropriate type of surgery according to the extent of nodal involvement: either SNB or complete axillary clearance.

NCT ID: NCT04039893 Recruiting - Clinical trials for Node-positive Breast Cancer

MUltimodal Targeted Axillary Surgery

MUTAS
Start date: October 23, 2019
Phase: N/A
Study type: Interventional

The present trial will prospectively evaluate the accuracy of both a systematic predefined axillary ultrasound imaging together with tumor load quantification of suspicious and sentinel axillary lymph nodes to predict overall tumor load in the axilla.

NCT ID: NCT03513614 Recruiting - Clinical trials for Node-positive Breast Cancer

Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS)

TAXIS
Start date: August 7, 2018
Phase: N/A
Study type: Interventional

RATIONALE: The use of tailored axillary dissection as a tailored procedure will avoid surgical overtreatment by selectively removing the lymph nodes that are affected by the cancer, thereby sparing many women the unnecessary complications of a radical surgery, providing a better quality of life while keeping the same efficacy. PURPOSE: The phase III trial is evaluating the optimal treatment for breast cancer patients in terms of surgery and radiotherapy.

NCT ID: NCT03413761 Completed - Clinical trials for Node Positive Breast Cancer

Antioxidant Supplements, Genetics and Chemotherapy Outcomes

Start date: December 18, 2004
Phase:
Study type: Observational

This study will investigate the null hypothesis that use of antioxidant supplements during adjuvant chemotherapy will have no impact on toxicities and disease-free, as well as overall, survival, and also evaluate the role of polymorphisms in genes related to oxidative stress in relation to treatment outcomes.

NCT ID: NCT02515110 Active, not recruiting - Breast Cancer Clinical Trials

Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer

Start date: August 4, 2015
Phase: N/A
Study type: Interventional

Single-arm, phase 2 study evaluating hypofractionated irradiation of breast and regional nodes in women with breast cancer. Patients will be grouped in 3 surgery-related treatment groups: 1) An intact breast following lumpectomy; 2) plans for loco regional external beam radiotherapy (EBRT) following mastectomy (with or without plans for reconstruction); and 3) plans for locoregional EBRT following mastectomy with reconstruction. Patients will be assessed for lymphedema, arm function, breast or chestwall pain, other EBRT-related adverse events, and, for patients who had a lumpectomy or mastectomy with reconstruction, cosmetic outcome.

NCT ID: NCT02348684 Completed - Clinical trials for Node Positive Breast Cancer

Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation

Start date: March 2012
Phase:
Study type: Observational

The association between radiation exposure and cardiac disease is well recognized, it is not fully understood if there exists an optimal or "safe" radiation dose-volume relationship.